Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.

Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A.

J Immunother. 2011 Sep;34(7):556-67. doi: 10.1097/CJI.0b013e3182280db1.

2.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.

J Clin Oncol. 2007 Feb 10;25(5):540-7.

PMID:
17290063
3.

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S.

Cancer Immunol Immunother. 2006 Dec;55(12):1524-33. Epub 2006 Apr 13.

PMID:
16612599
4.

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP, Israel R, Scher HI, Morris S.

Vaccine. 2013 Jan 30;31(6):943-9. doi: 10.1016/j.vaccine.2012.11.096. Epub 2012 Dec 13.

PMID:
23246260
5.

Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.

Arndt C, Feldmann A, Koristka S, Cartellieri M, Dimmel M, Ehninger A, Ehninger G, Bachmann M.

Prostate. 2014 Sep;74(13):1335-46. doi: 10.1002/pros.22850. Epub 2014 Jul 22.

PMID:
25053443
6.

Immunotherapy for prostate cancer.

Fong L, Small EJ.

Semin Oncol. 2003 Oct;30(5):649-58. Review.

PMID:
14571412
7.
8.

[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].

Zhuang ZX, Shen LQ, Shi Y, Lu X, Shi HZ.

Zhonghua Nan Ke Xue. 2010 Aug;16(8):698-704. Chinese.

PMID:
21090344
9.

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.

Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL.

Prostate. 1999 Jan 1;38(1):73-8.

PMID:
9973112
10.

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY.

Clin Cancer Res. 2003 Aug 15;9(9):3260-71.

11.

Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.

Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M.

Clin Cancer Res. 2002 Dec;8(12):3885-92.

12.

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.

Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK.

Eur J Immunol. 2011 Aug;41(8):2447-56. doi: 10.1002/eji.201141518. Epub 2011 Jul 4.

13.

A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.

Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC.

Clin Cancer Res. 2007 Jul 1;13(13):3999-4008.

14.

Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.

Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, Heston WD, Houghton AN, Scher HI.

Int J Cancer. 2005 Sep 1;116(3):415-21.

16.

The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.

Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM.

Prostate. 2009 Feb 1;69(2):142-8. doi: 10.1002/pros.20864.

PMID:
18942640
17.

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).

Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP.

Prostate. 1998 May;35(2):144-51.

PMID:
9568678
18.

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT.

Eur Urol. 2000 Aug;38(2):208-17.

PMID:
10895014
19.

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E.

Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.

PMID:
25327986
20.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.

Clin Cancer Res. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28.

Supplemental Content

Support Center